UPCC 35922: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Enrolling By Invitation
99 years and younger
All
Phase
1
1 Location
Brief description of study
Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
10 May 2023.
Study ID: 852931
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
